Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPB1 | P04792 | 3/20 | 0.58 |
| ▸ | AR | P10275 | 1/20 | 0.48 |
| ▸ | SCN4A | P35499 | 1/20 | 0.45 |
| ▸ | TRPA1 | O75762 | 5/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.42 |
| ▸ | PNLIP | P16233 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14959581 | 0.89 | HSPB1 (0.50) | HSPB1ARSCN4ATRPA1APP | |
| SCHEMBL13860118 | 0.85 | HSPB1 (0.42) | HSPB1ARAPPHTR2ASLC6A4 | |
| SCHEMBL14965305 | 0.81 | CYP1A2 (0.47) | HSPB1HTR2ASLC6A4KCNH2LMNA | |
| SCHEMBL18646614 | 0.81 | HSPB1 (0.58) | HSPB1ARSCN4APNLIPHTR2A | |
| SCHEMBL4374841 | 0.81 | HSPB1 (0.58) | HSPB1ARSCN4ATRPA1MAPK14 | |
| SCHEMBL9339651 | 0.81 | HSPB1 (0.58) | HSPB1ARSCN4ATRPA1MAPK14 | |
| SCHEMBL9342871 | 0.81 | HSPB1 (0.58) | HSPB1ARSCN4ATRPA1PNLIP | |
| SCHEMBL8298015 | 0.81 | HSPB1 (0.58) | HSPB1ARSCN4ATRPA1MAPK14 | |
| SCHEMBL1584863 | 0.80 | PARP10 (0.56) | APPLMNA | |
| SCHEMBL10456772 | 0.79 | TRPA1 (0.56) | HSPB1ARTRPA1MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115716827-A | Iminosulfones compound as bromodomain protein inhibitor, pharmaceutical composition and medical application thereof | 正大天晴药业集团股份有限公司 | 2023-02-28 | — | — | CN | disclosed |
| CN-112424200-B | Iminosulfones compound as bromodomain protein inhibitor, pharmaceutical composition and medical application thereof | 正大天晴药业集团股份有限公司 | 2022-09-20 | — | — | CN | disclosed |
| US-7625932-B2 | Pyrrole and pyrazole derivatives as potentiators of glutamate receptors | ELI LILLY AND COMPANY (US) | 2009-12-01 | — | — | US | disclosed |
| US-7625932-B2 | Pyrrole and pyrazole derivatives as potentiators of glutamate receptors | ELI LILLY AND COMPANY (US) | 2009-12-01 | — | — | US | disclosed |
| US-7625932-B2 | Pyrrole and pyrazole derivatives as potentiators of glutamate receptors | ELI LILLY AND COMPANY (US) | 2009-12-01 | — | — | US | disclosed |
| EP-1670757-B1 | PYRROLE AND PYRAZOLE DERIVATIVES AS POTENTIATORS OF GLUTAMATE RECEPTORS | LILLY CO ELI (US) | 2009-05-06 | — | — | EP | disclosed |
| EP-1670757-B1 | PYRROLE AND PYRAZOLE DERIVATIVES AS POTENTIATORS OF GLUTAMATE RECEPTORS | LILLY CO ELI (US) | 2009-05-06 | — | — | EP | disclosed |
| US-20070066573-A1 | Pyrrole and pyrazole derivatives as potentiators of glutamate receptors | ELI LILLY AND COMPANY | 2007-03-22 | — | — | US | disclosed |
| US-20070066573-A1 | Pyrrole and pyrazole derivatives as potentiators of glutamate receptors | ELI LILLY AND COMPANY | 2007-03-22 | — | — | US | disclosed |
| US-20070066573-A1 | Pyrrole and pyrazole derivatives as potentiators of glutamate receptors | ELI LILLY AND COMPANY | 2007-03-22 | — | — | US | disclosed |
| WO-2005040110-A1 | PYRROLE AND PYRAZOLE DERIVATIVES AS POTENTIATORS OF GLUTAMATE RECEPTORS | ELI LILLY AND COMPANY (US) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066573-A1 | Pyrrole and pyrazole derivatives as potentiators of glutamate receptors | GRIN1, GRIN3A, GRIK5 | HSPB1 4378/4885AR 3300/4885SCN4A 2561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.